The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
Abstract
Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly spliced due to a silent mutation within an exonic splicing enhancer in exon 7. However, correct splicing can be restored by over-expression of the SR-like splicing factor Htra2-beta 1. We show that in fibroblast cultures derived from SMA patients treated with therapeutic doses (0.5-500 microM) of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold. Importantly, this up-regulation of SMN could be most likely attributed to increased levels of Htra2-beta 1 which facilitates the correct splicing of SMN2 RNA as well as to an SMN gene transcription activation. Especially at low VPA concentrations, the restored SMN level depended on the number of SMN2 copies. Moreover, VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats. Finally, VPA also increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing. Since VPA is a drug highly successfully used in long-term epilepsy therapy, our findings open the exciting perspective for a first causal therapy of an inherited disease by elevating the SMN2 transcription level and restoring its correct splicing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P.-A., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,089
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Wirth, B. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200003)15:3<228::aid-humu3>3.0.co;2-9 · Cited by 667
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
Cited by
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Le, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 598
Metadata
- Authors
- Brichta, L.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Brichta, L.
- ORCID
- Brichta, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2481-2489
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151318390
- Cited by
- 382
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 15 · 2013: 31 · 2012: 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- valproic acid, spinal muscular atrophy, SMN2, SMN1, SR proteins, alternative splicing, exonic splicing enhancers, drug repurposing, inherited neuromuscular disease
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Exons, Fibroblasts, Gene Expression Regulation, Hippocampus, Humans, Muscular Atrophy, Spinal, Nerve Tissue Proteins, Organ Culture Techniques, RNA Splicing, RNA, Messenger, Time Factors, Transcription, Genetic, Valproic Acid, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Deletion, GABA Agents, Reverse Transcriptase Polymerase Chain Reaction, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. https://app.cochat.ai/papers/10.1093/hmg/ddg256
- The paper
- Brichta, L. (2003). Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddg256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.